Clinical trials: sponsored by UNICANCER
Metastatic Breast Cancer
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Open label multicentric phase II randomized trial, using high throughput genome analysis as a therapeutic decision tool, which aims at comparing a targeted treatment administered according to the identified molecular anomalies of…
- Trial name
- SAFIR02_Breast (NCT02299999)
- Testing
- AZD2014, AZD4547, AZD5363
- Where
- 25 sites in France
- Volunteers
- 1,460 people
- Sponsor
- UNICANCER
Advanced Solid Tumours, Breast Cancer
Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
This is a phase I/II national, multicentre, multiple cohort, prospective open-label, non-randomised and non-comparative study, to evaluate the safety and activity of metronomic oral vinorelbine associated with durvalumab +…
- Conditions
- Advanced Solid Tumours, Breast Cancer, Head and Neck Cancer, Cervix Cancer
- Trial name
- MOVIE (NCT03518606)
- Testing
- Durvalumab + Tremelimumab + metronomic Vinorelbine
- Where
- 9 sites in France
- Volunteers
- 126 people
- Sponsor
- UNICANCER
Local Recurrence of Malignant Tumor of Prostate
Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence
Stereo-Re-Pro aims to provide further evidence of Stereotactic Body Radiotherapy (SBRT) as a supplementary non-invasive curative treatment for local recurrence following radiotherapy.
- Trial name
- STEREO-RE-PRO (NCT03438552)
- Testing
- Stereotactic Body Radiotherapy
- Where
- 12 sites in France
- Volunteers
- 57 people
- Sponsor
- UNICANCER
Prostatic Cancer, Castration-Resistant
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
In earlier stages of prostate cancer, male sexual hormones (androgens) stimulate the growth of cancer cells. Castration-resistant prostate cancer (CRPC) means that the prostate cancer continued to grow despite patients are taking…
- Trial name
- PEACE8 (NCT06276465)
- Testing
- Darolutamide 300 mg, Stereotactic body radiation therapy, Androgen deprivation therapy
- Where
- 4 sites in France
- Volunteers
- 336 people
- Sponsor
- UNICANCER
Prostate Cancer Metastatic
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
PEACE-6 Poor Responders is an international, multicenter, open-label, controlled, randomized, phase III trial to evaluate the efficacy and safety of 177Lu-PSMA-617 when administered on top of the ongoing standard systemic…
- Trial name
- NCT06496581
- Testing
- 177Lu-PMSA-617, Standard of Care
- Where
- 25 sites in France
- Volunteers
- 500 people
- Sponsor
- UNICANCER
Adenocarcinoma of Prostate
Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy
The purpose of this study is to select the best therapeutic strategy in studying the effectiveness of the association of a short duration hormonal therapy and radiotherapy compared with radiotherapy alone, in patients with a…
- Trial name
- GETUG-AFU22 (NCT01994239)
- Testing
- Degarelix, Pelvic Radiotherapy
- Where
- 39 sites in France
- Volunteers
- 120 people
- Sponsor
- UNICANCER
Bladder Cancer
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
This is an open-label, randomized, multicentric study in patients with high-risk non-muscle invasive bladder cancer who had never received BCG for this disease.
- Trial name
- ALBAN (NCT03799835)
- Testing
- BCG, Atezolizumab
- Where
- 38 sites in Belgium, France and 1 more
- Volunteers
- 517 people
- Sponsor
- UNICANCER
Patients With High-risk MIBC
Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)
This is a randomized multicentre study in patients with high-risk MIBC to investigate adjuvant radiotherapy after radical cystectomy and pelvic lymph node dissection.
- Trial name
- Bladder-ART (NCT03333356)
- Testing
- pelvic radiotherapy
- Where
- 17 sites in France
- Volunteers
- 81 people
- Sponsor
- UNICANCER
Metastatic Prostate Cancer
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
This is a multi-center phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient…
- Trial name
- PEACE1 (NCT01957436)
- Testing
- abiraterone acetate, radiotherapy, Androgen Deprivation Therapy
- Where
- 77 sites in Belgium, France and 5 more
- Volunteers
- 1,173 people
- Sponsor
- UNICANCER
Breast Cancer
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
The main objective of this multicenter study will therefore be to evaluate pathologic complete response rates of an anthracycline-based regimen [FEC 100 - TAXOTERE® - HERCEPTIN® - PERTUZUMAB] and a non anthracycline-based regimen…
- Trial name
- NeoTOP (NCT02339532)
- Testing
- FEC100, Docetaxel, Trastuzumab
- Where
- 12 sites in France
- Volunteers
- 86 people
- Sponsor
- UNICANCER
Breast Cancer Nos Metastatic Recurrent, Early Lung Cancer
Chronic Toxicities Related to Treatment in Patients With Localized Cancer
The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic cancer.
- Trial name
- CANTO (NCT01993498)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 14,750 people
- Sponsor
- UNICANCER
Colorectal Cancer Metastatic
Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network
National trial, multicenter, randomized, phase II comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy (CT) to systemic chemotherapy alone in patients with liver-only…
- Trial name
- SULTAN (NCT03164655)
- Testing
- Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil
- Where
- 4 sites in France
- Volunteers
- 20 people
- Sponsor
- UNICANCER
Metastases
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
PRINCIPAL OBJECTIVE: Evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients…
- Trial name
- NCT01442246
- Testing
- Leuprorelin Acetate
- Where
- 35 sites in France
- Volunteers
- 700 people
- Sponsor
- UNICANCER
brca1 Mutation Carrier, brca2 Mutation Carrier
Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
RATIONALE: Letrozole may prevent breast cancer in postmenopausal women with a BRCA1 or BRCA2 mutation. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in preventing…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
- Trial name
- LIBER (NCT00673335)
- Testing
- letrozole
- Where
- 23 sites in France
- Volunteers
- 170 people
- Sponsor
- UNICANCER
Breast Cancer Female
Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence
The standard treatment of localized breast cancers consists of surgical removal of the tumor at the breast or removal of the entire breast and lymph nodes (sentinel lymph node and / or axillary dissection) with or without…
- Trial name
- HYPOG-01 (NCT03127995)
- Testing
- HYPOFRACTIONATED, NORMOFRACTIONATED
- Where
- 28 sites in France
- Volunteers
- 1,265 people
- Sponsor
- UNICANCER
Hematologic Cancers, Solid Tumors
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
This is a biology driven, trans-tumoral, multicentric phase II trial assessing the efficacy and the safety of the targeted agent crizotinib as a monotherapy in 23 cohorts of patients with identified activating molecular…
- Conditions
- Hematologic Cancers, Solid Tumors, Metastatic Cancer
- Trial name
- AcSé (NCT02034981)
- Testing
- Crizotinib
- Where
- France
- Volunteers
- 246 people
- Sponsor
- UNICANCER
Carcinoma, Renal Cell, Head and Neck Neoplasm
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in 6 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Carcinoma, Renal Cell, Head and Neck Neoplasm, Skin Neoplasms, Microsatellite Instability
- Trial name
- AcSé (NCT03012581)
- Testing
- Nivolumab
- Where
- France
- Volunteers
- 269 people
- Sponsor
- UNICANCER
Sarcoma, Ovarian Neoplasm
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm
- Trial name
- AcSé (NCT03012620)
- Testing
- Pembrolizumab
- Where
- France
- Volunteers
- 334 people
- Sponsor
- UNICANCER
Breast Cancer
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- TavIx (NCT00630032)
- Testing
- cyclophosphamide, Docetaxel, epirubicin hydrochloride
- Where
- 86 sites in United States, Belgium and 1 more
- Volunteers
- 762 people
- Sponsor
- UNICANCER
Non-small Cell Lung Cancer Metastatic
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
Open label multicentric randomized phase II trial, using high throughput genome analysis as a therapeutic decision tool, aimed at comparing a targeted treatment administered according to the identified molecular anomalies of the…
- Trial name
- SAFIR02_Lung (NCT02117167)
- Testing
- AZD2014, AZD4547, AZD5363
- Where
- 37 sites in France
- Volunteers
- 999 people
- Sponsor
- UNICANCER